204 related articles for article (PubMed ID: 23007482)
21. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.
Dhimolea E; Reichert JM
MAbs; 2012; 4(1):4-13. PubMed ID: 22327426
[TBL] [Abstract][Full Text] [Related]
22. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.
Ahmed M; Cheung NK
FEBS Lett; 2014 Jan; 588(2):288-97. PubMed ID: 24295643
[TBL] [Abstract][Full Text] [Related]
23. Keystone Symposium on Antibodies as Drugs: March 27-April 1, 2009, Whistler, BC CA.
Wurch T; Larbouret C; Robert B
MAbs; 2009; 1(4):318-25. PubMed ID: 20068403
[TBL] [Abstract][Full Text] [Related]
24. Emerging trends and therapeutic applications of monoclonal antibodies.
Mekala JR; Nalluri HP; Reddy PN; S B S; N S SK; G V S D SK; Dhiman R; Chamarthy S; Komaragiri RR; Manyam RR; Dirisala VR
Gene; 2024 Oct; 925():148607. PubMed ID: 38797505
[TBL] [Abstract][Full Text] [Related]
25. 9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.
Reichert JM; Beck A; Lugovskoy AA; Wurch T; Coats S; Brezski RJ
MAbs; 2014; 6(2):309-26. PubMed ID: 24492298
[TBL] [Abstract][Full Text] [Related]
26. Engineering antibodies for therapy.
Presta LG
Curr Pharm Biotechnol; 2002 Sep; 3(3):237-56. PubMed ID: 12164480
[TBL] [Abstract][Full Text] [Related]
27. Highlights of Antibody Engineering and Therapeutics 2019 in San Diego, USA: Bispecific Antibody Design and Clinical Applications.
Zhu Y; Shen R; Hao R; Wang S; Ho M
Antib Ther; 2020 Apr; 3(2):146-154. PubMed ID: 32671329
[TBL] [Abstract][Full Text] [Related]
28. 7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France.
Pauwels PJ; Dumontet C; Reichert JM; Beck A; Goetsch L; Corvaia N; Klein C; Coiffier B; Teicher B
MAbs; 2012; 4(4):434-44. PubMed ID: 22684281
[TBL] [Abstract][Full Text] [Related]
29. The state-of-play and future of antibody therapeutics.
Elgundi Z; Reslan M; Cruz E; Sifniotis V; Kayser V
Adv Drug Deliv Rev; 2017 Dec; 122():2-19. PubMed ID: 27916504
[TBL] [Abstract][Full Text] [Related]
30. Recombinant bispecific antibodies for cellular cancer immunotherapy.
Müller D; Kontermann RE
Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
[TBL] [Abstract][Full Text] [Related]
31. Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany.
Beck A; Lambert J; Sun M; Lin K
MAbs; 2012; 4(6):637-47. PubMed ID: 22909934
[TBL] [Abstract][Full Text] [Related]
32. Frontiers and Opportunities: Highlights of the 2
Zhang H; Deng M; Lin P; Liu J; Liu C; Strohl WR; Wang S; Ho M
Antib Ther; 2018 Sep; 1(2):65-74. PubMed ID: 30406214
[TBL] [Abstract][Full Text] [Related]
33. Antibody engineering--IBC's Tenth International Conference. 6-9 December 1999, La Jolla, CA, USA.
Carter P
IDrugs; 2000 Mar; 3(3):259-61. PubMed ID: 16103927
[TBL] [Abstract][Full Text] [Related]
34. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
Gu J; Ghayur T
Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
[TBL] [Abstract][Full Text] [Related]
35. Metastasis Research Society VII International Congress (Part II). 7-10 October 1998, San Diego, CA, USA.
Chambers AF
Acta Histochem; 1999 Feb; 101(1):12-7. PubMed ID: 10093641
[TBL] [Abstract][Full Text] [Related]
36. The therapeutic use of antibodies for malignancy.
Johnson PW
Transfus Clin Biol; 2001 Jun; 8(3):255-9. PubMed ID: 11499972
[TBL] [Abstract][Full Text] [Related]
37. Antibody engineering: facing new challenges in cancer therapy.
Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L
Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728
[TBL] [Abstract][Full Text] [Related]
38. Improving the efficacy of antibody-based cancer therapies.
Carter P
Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
[TBL] [Abstract][Full Text] [Related]
39. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
Niwa R; Satoh M
J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
[TBL] [Abstract][Full Text] [Related]
40. Antibody-based therapeutics in oncology.
Ross J; Gray K; Schenkein D; Greene B; Gray GS; Shulok J; Worland PJ; Celniker A; Rolfe M
Expert Rev Anticancer Ther; 2003 Feb; 3(1):107-21. PubMed ID: 12597355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
